Abstract 544P
Background
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape. While programmed death-ligand 1 expression serves as a predictive biomarker, uncovering extra ICI response markers is pivotal. Immune cell transcriptomic analysis is a promising path for identifying such markers. Our study aims to find an ICI response predictor in lung adenocarcinoma patients' peripheral blood mononuclear cells (PBMC) through single-cell RNA sequencing (scRNA-seq).
Methods
We prospectively collected PBMC from 38 patients with stage IV lung adenocarcinoma, both before (0-7 days) and after (1-3 weeks) treatment with anti-PD(L)-1 therapy. Among the patients, 17 achieved a partial response, 4 had stable disease, and 17 experienced disease progression. Patients with a partial response or stable disease were classified as responders, while those with disease progression were classified as non-responders. We performed scRNA-seq on PBMC to unravel the molecular landscape.
Results
Subgroup analysis of NKT cells in pre-treated state revealed upregulated RNA expression related to activator protein 1 (AP-1) signals in NK cell subtypes (CD56lowCD16int NK cell, CCL4 NK cell, PTGDS NK cell) in responders. CD56 high CD16 low expressing NK cells were increased in responder after treatment with ICI. Additionally, we found an increased proportion of monocytes with high CXCL10 expression in the responder group. Signals associated with chemokine ligands and interferon-inducible proteins were upregulated in monocyte subtypes prior to ICI treatment.
Conclusions
Our scRNA-seq analysis of PBMC from lung adenocarcinoma patients provided valuable insights into the immune landscape. Upregulation of AP-1 signals in NK cells and chemokine ligand expression, as well as interferon-inducible signals in monocytes, were observed in responders prior to ICI treatment. Moreover, the expansion of monocytes with high CXCL10 expression in the responder group suggests the potential involvement of these circulating immune cell populations in the anti-tumor immune response. These findings contribute to our understanding of ICI response and offer promise for the future development of predictive biomarkers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract